跳转至内容
Merck
CN

Y0001630

用于系统适应性A的泼尼甲酸盐

European Pharmacopoeia (EP) Reference Standard

别名:

泼尼卡酯

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C27H36O8
化学文摘社编号:
分子量:
488.57
EC 号:
UNSPSC代码:
41116107
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

pharmaceutical primary standard

API类

prednicarbate

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

O(C1(C2(C(C3C(C4(C(=CC(=O)C=C4)CC3)C)C(C2)O)CC1)C)C(=O)COC(=O)CC)C(=O)OCC

InChI

1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3

InChI key

FNPXMHRZILFCKX-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Prednicarbate for system suitability A EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Health hazard

警示用语:

Danger

危险声明

预防措施声明

危险分类

Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

V Niemeier et al.
The Journal of dermatological treatment, 16(2), 95-101 (2005-07-16)
The treatment of atopic dermatitis still remains a challenge. Little research has been done on the issue of the extent to which patients correctly use prescribed topical preparations under everyday conditions. To investigate what quantity of topical preparations is applied
Aditya K Gupta et al.
Journal of cutaneous medicine and surgery, 8(4), 244-247 (2005-08-11)
Topical steroids have been a popular choice for treating various cutaneous disorders; however, the potential for significant local and systemic adverse events, like skin atrophy and hypothalamic-pituitary-adrenal (HPA) axis suppression, has limited their use. This article reviews the topical steroid
Kerstin Katzer et al.
European journal of dermatology : EJD, 20(1), 82-84 (2009-10-03)
The epidermal growth factor receptor (EGFR) inhibitor cetuximab is used to treat advanced stages of solid tumors. Acneiform skin eruptions, the most common side effects of cetuximab, stigmatize the patient in daily life and may lower compliance. As oral treatment
I Spika et al.
Skin pharmacology and applied skin physiology, 16(3), 143-150 (2003-04-05)
As compared to standard glucocorticoids (GC), prednicarbate (PC) is favorable in the treatment of eczema due to its high benefit/risk ratio. The remarkable anti-inflammatory effects of PC are in strong contrast to its reported low glucocorticoid receptor (GR) binding affinity.
Aditya K Gupta et al.
Journal of drugs in dermatology : JDD, 3(5), 553-556 (2004-11-24)
Prednicarbate is a non-halogenated, double-ester derivative of prednisolone that has become of interest for the treatment of inflammatory skin diseases, for example atopic dermatitis. In the past, topical steroids have been a popular choice for treating these diseases; however, the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持